Product Name:
Hck-ANT
Product Number:
ab-nk271-1
Target Full Name: Tyrosine-protein kinase Hck
Target Alias: B-cell, myeloid kinase; B-cell/myeloid kinase; BMK; Hemopoietic cell kinase; JTK9; Kinase Hck; p56-Hck and p60-Hck; p59-Hck; p60-Hck; RP5-836N17_3; ENSG00000101336
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK271-1
Antibody Target Type: Pan-specific
Protein UniProt: P08631
Protein SigNET: P08631
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Hck sequence peptide Cat. No.: PE-01BDC80
Antibody Immunogen Sequence: CMKSKFLQVGGNTFSKTETS
Antibody Immunogen Description: Corresponds to amino acid residues C24 to S43; Post-N-terminus
Production Method: Corresponds to amino acid residues C24 to S43; Post-N-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 0.75 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 55-60 kDa.
Related Product 1: Hck-ANT blocking peptide
Scientific Background: Hck is a protein-tyrosine kinase of the TK group and Src family. This kinase is highly expressed and widely distributed in most tested human tissues. Hck is especially expressed in certain hemopoietic cells and especially prominent in cells of myeloid lineage, particularly mature granulocytes and monocytes. It plays important roles in the regulation of the innate immune responses including leukocyte function, phagocytosis, survival and proliferation, cell adhesion and migration. It promotes the reorganization of the actin cytoskeleton and actin polymerization, as well as the formation of podosomes. Hck is also involved in the release of inflammatory molecules from the cell, and can inhibit TP73-mediated apoptosis. Aberrant activation of Hck by the BCR-Abl protein promotes cancer cell proliferation. A D399G mutation was associated with an ovarian mucinous carcinoma sample. Hck is inhibited by phosphorylation at Y522. Hck may be an oncoprotein (OP) based on its similarity to other Src family kinases that are known oncoproteins. The active form of the protein kinase normally acts to promote tumour cell proliferation. Hck has been linked with Adenosquamous carcinoma, which is a mixed lineage carcinoma made of squamous and gland cells. Hck is activated by the HIV-1 protein Nef. Its catalytic activity can be impaired, yet affinity for target peptides increased with a Y411A mutation. The Y522F mutation will constitutively activate the kinase, leading to cellular pertubations and transformation. Phosphorylation of Y522 of Hck inhibits its phosphotransferase activity. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.